Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Infection of MSCs by adenovirus expression system expressing NRF2 as a cytoprotective factor. (English)
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Mohammadzadeh, M.; Halabian, R.; Mohammadipoor, M.; Kiani, A. A.; Gharehbaghian, A.; Amirizadeh, N.; Roudkenar, M. Habibi
- Source:
Scientific Journal of Iranian Blood Transfusion Organization; Jan2012, Vol. 8 Issue 4, p272-285, 14p
- Subject Terms:
- Additional Information
- Abstract:
Background and Objectives Poor viability of Mesenchymal Stem Cells (MSCs) following transplantation is one of the major challenges in their therapeutic application. Manipulation of MSCs by the genetic engineering method is one of the strategies used to protect the cells against cytotoxic microenvironment. However, maintaining multi differentiation capacity of MSCs following manipulation is important. We investigated if the manipulation of MSCs with NRF2 affects the multi differentiation capacity. Materials and Methods MSCs were isolated from bone marrow. NRF2 was isolated and TOPO cloned into the pENTR vector. The recombinant vector was transferred into pAD/CMV/V5-DEST vector by gateway technology. Recombinant adenovirus was produced in AD293 cells, followed by being infected into MSCs. Expression of NRF2 was verified by RT-PCR. The NRF2 engineered MSCs were exposed to stress conditions followed by the evaluation of the cells viability and apoptosis. Finally, NRF2 expressing MSCs differentiation into osteoblast and adipocyte lineages was studied. Results NRF2 was successfully expressed in MSCs. NRF2- MSCs differentiation into osteoblast and adipocyte lineages indicating overexpression of NRF2 does not affect the differentiation property of MSCs. Conclusions Expression of NRF2, a well known cytoprotective factor, by using adenovirus expression system does not intervene in the differentiation capacity of MSCs. NRF2-MSCs might be applicable for stem cell-based cell therapy in future. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Scientific Journal of Iranian Blood Transfusion Organization is the property of Iranian Blood Transfusion Organization Research Center and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.